We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+52.12%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
–
AUM
$2.58B
AUM Growth
+$1.06B
Cap. Flow
+$1.07B
Cap. Flow %
41.35%
Top 10 Hldgs %
67.03%
Holding
812
New
224
Increased
195
Reduced
131
Closed
143

Top Buys

Rank Stock Value
1
COIN icon
Coinbase
COIN
+$211M
2
NVDA icon
NVIDIA
NVDA
+$146M
3
META icon
Meta Platforms (Facebook)
META
+$111M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$42.4M
5
AAPL icon
Apple
AAPL
+$35.7M

Top Sells

Rank Stock Value
1
XLE icon
State Street Energy Select Sector SPDR ETF
XLE
+$33M
2
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$30.3M
3
IMCR icon
Immunocore
IMCR
+$28.5M
4
SIRI icon
SiriusXM
SIRI
+$26.6M
5
IMO icon
Imperial Oil
IMO
+$24.7M

Sector Composition

Rank Sector Weight
1 Financials 29.84%
2 Technology 29.38%
3 Healthcare 23.72%
4 Communication Services 6.1%
5 Energy 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDA icon
1
NVIDIA
NVDA
$4.86T
$675M 26.15%
7,472,120
+2,010,230
+37% +$146M
COIN icon
2
Coinbase
COIN
$39.6B
$409M 15.83%
1,541,904
+1,170,433
+315% +$211M
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$144M 5.56%
5,629,103
– –
META icon
4
Meta Platforms (Facebook)
META
$1.41T
$140M 5.41%
287,632
+248,167
+629% +$111M
PTCT icon
5
PTC Therapeutics
PTCT
$5.71B
$108M 4.2%
3,725,626
– –
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.57B
$77.2M 2.99%
2,122,530
+211,131
+11% +$6.21M
ESTA icon
7
Establishment Labs
ESTA
$2.73B
$47.8M 1.85%
939,948
– –
STOK icon
8
Stoke Therapeutics
STOK
$1.8B
$45.4M 1.76%
3,365,744
-355,915
-10% -$2.16M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.77B
$45.1M 1.75%
+1,557,636
New +$42.4M
AAPL icon
10
Apple
AAPL
$4.49T
$39.4M 1.53%
229,968
+196,456
+586% +$35.7M
FULC icon
11
Fulcrum Therapeutics
FULC
$237M
$35.1M 1.36%
3,713,934
+240,000
+7% +$2.14M
SMFG icon
12
Sumitomo Mitsui Financial
SMFG
$165B
$33M 1.28%
+2,800,730
New +$30M
MERC icon
13
Mercer International
MERC
$42.2M
$32.8M 1.27%
3,300,000
– –
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$340M
$29.6M 1.15%
1,100,000
– –
CVII
15
DELISTED
Churchill Capital Corp VII Class A Common Stock
CVII
$28.4M 1.1%
2,652,184
-978,038
-27% -$10.4M
BABA icon
16
Alibaba
BABA
$291B
$28.2M 1.09%
389,543
+70,392
+22% +$5.16M
ET icon
17
Energy Transfer Partners
ET
$70.2B
$28M 1.08%
1,777,000
– –
URGN icon
18
UroGen Pharma
URGN
$1.87B
$24.4M 0.95%
+1,626,589
New +$26.6M
SPY icon
19
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$14.9M 0.58%
+28,554
New +$14.2M
ANSC
20
Agriculture & Natural Solutions Acquisition Corp
ANSC
$476M
$13.6M 0.53%
+1,335,931
New +$13.5M
CYTK icon
21
CALL
Cytokinetics
CYTK
$10.5B
$13.1M 0.51%
+510,000
New +$39.4M
EEM icon
22
iShares MSCI Emerging Markets ETF
EEM
$28.8B
$12.2M 0.47%
+297,745
New +$11.8M
PWR icon
23
Quanta Services
PWR
$101B
$11.4M 0.44%
+44,037
New +$9.74M
RRAC
24
DELISTED
Rigel Resource Acquisition Corp.
RRAC
$11.4M 0.44%
1,019,434
-157,059
-13% -$1.74M
PHYT
25
DELISTED
Pyrophyte Acquisition Corp.
PHYT
$11.1M 0.43%
997,063
+435,695
+78% +$4.84M
1
2 3 4 5

Similar funds

CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
PWLP
Prio Wealth Limited Partnership Boston, Massachusetts $3.41B AUM 44.09% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
SI
Scout Investments Kansas City, Missouri $3.8B AUM 45.91% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return

Cowen and Company's Q1 2024 Portfolio in Review

As of Q1 2024, Cowen and Company held 812 positions worth $2.58B, up 69% from $1.52B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Cowen and Company deployed $1.07B of net new capital in Q1 2024, opening 224 new positions and adding to 195 existing holdings. Its largest new stake was Protagonist Therapeutics: 1,557,636 shares worth $45.1M.

By sector, the portfolio is most concentrated in Financials at 30% of assets, up from 25% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Screaming Eagle Acquisition Corp. Class A Ordinary Shares, an estimated $30.3M trimmed.

  • Cowen and Company's largest Q1 2024 buy was Protagonist Therapeutics: 1,557,636 shares worth $45.1M.
  • Cowen and Company added most to Coinbase in Q1 2024, an estimated $211M increase.
  • Cowen and Company's biggest Q1 2024 reduction was Screaming Eagle Acquisition Corp. Class A Ordinary Shares, cutting an estimated $30.3M.
  • Cowen and Company fully exited State Street Energy Select Sector SPDR ETF in Q1 2024, selling an estimated $33M.
  • Cowen and Company's ten largest holdings make up 67% of its $2.58B portfolio in Q1 2024.
  • Cowen and Company opened 224 new positions and closed 143 in Q1 2024.
  • Cowen and Company's portfolio value rose 69% quarter-over-quarter to $2.58B.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.